Neurological
Refine Search
Pharmaceutical
Jazz Pharmaceuticals has reported third-quarter revenue of $1 billion, a 9% increase over the prior year, fueled by strong performance in its key sleep and epilepsy portfolios. 7 November 2024
Biotechnology
US clinical-stage drug developer Acumen Pharmaceuticals has appointed Amy Schacterle as chief regulatory officer and head of quality, reporting to Jim Doherty, president and chief development officer at Acumen. 7 November 2024
Pharmaceutical
Intra-Cellular Therapies has announced positive results from Study 304 evaluating the efficacy and safety of Caplyta (lumateperone) 42mg for the prevention of relapse in adult patients with schizophrenia. 6 November 2024
Pharmaceutical
US neuroscience-focused biopharma Neurocrine Biosciences presented new data from more than 300 patients diagnosed with tardive dyskinesia and treated with Ingrezza (valbenazine) capsules at the 2024 Psych Congress in Boston. 5 November 2024
Pharmaceutical
Privately-held German drugmaker Boehringer Ingelheim and researchers from the Stanley Center for Psychiatric Research at the Broad Institute of MIT and Harvard, are collaborating on a project to tackle the urgent and unmet needs of people living with mental health conditions. 4 November 2024
Pharmaceutical
US pharma major AbbVie last week proposed $1.4 billion acquisition of US CNS drug developer Aliada Therapeutics. Last week saw a bunch of third quarter 2024 financials results, among which were Elil Lilly, AbbVie and Merck & Co. Also of note, Lexicon’s type I diabetes drug Zynquista faced a Food and Drug Administration (FDA) advisory committee review that resulted in largely negative vote against recommendation. 3 November 2024
Pharmaceutical
The US subsidiary of Israel’s Teva Pharmaceutical Industries has announced new, positive data on social functioning and quality of life from the Phase III subcutaneous olanzapine extended-release injection study (SOLARIS) trial evaluating TEV-'749 in adult patients diagnosed with schizophrenia. 2 November 2024
Pharmaceutical
US pharma major AbbVie and Hungary’s Gedeon Richter have announced a new discovery, co-development and license agreement to advance novel targets for the potential treatment of neuropsychiatric conditions. 1 November 2024
Biotechnology
Dyno Therapeutics has recently announced the formation of a new strategic partnership with Swiss pharma giant Roche to develop adeno-associated virus (AAV) gene therapy vectors to target neurological diseases. 1 November 2024
Biotechnology
UCB has reported Phase IIa data from the TOGETHER (AH0003) study, investigating the safety, efficacy, and tolerability of bepranemab - an investigational anti-tau antibody targeting the mid-region of the tau protein - in people living with prodromal to mild Alzheimer’s disease. 1 November 2024
Biotechnology
Boston, USA-based biotech Axonis Therapeutics, which is focused on the development of novel neuromedicines, has announced the successful completion of an oversubscribed $115 million Series A financing. 31 October 2024
Biotechnology
US biotech companies Biogen and Neomorph have announced a research collaboration to discover and develop molecular glue degraders for priority targets in Alzheimer’s, rare neurological, and immunological diseases. 30 October 2024
Pharmaceutical
Swiss pharma giant Novartis revealed rising sales and earnings in its third-quarter financial results on Tuesday. 29 October 2024
Biotechnology
South Korea’s GemVax & KAEL has reported positive top-line results from a Phase IIa trial of GV1001, for progressive supranuclear palsy (PSP). 29 October 2024
Biotechnology
US Pharma major AbbVie has reached a definitive agreement to acquire Aliada Therapeutics, a biotech advancing therapies using a novel blood-brain barrier (BBB)-crossing technology to address challenging central nervous system (CNS) diseases. 29 October 2024
Biotechnology
Last week Vertex Pharmaceuticals released positive Phase III results for its suzetrigine for moderate-to-severed pain. Belgium’s UCB revealed that Swiss pharma giant Roche was terminating its collaboration on the Alzheimer’s candidate bepranemab. The UK’s health technology assessor the Institute for Health and Clinical Excellence (NICE) declined to recommend a second Alzheimer’s treatment, this time Eli Lilly’s Kisunla. Also of note, Lyell Immunopharma announced its planned acquisition of ImmPACT Bio and reprioritization of its own clinical pipeline. 27 October 2024
Pharmaceutical
Finnish pharma group Orion has announced it is discontinuing development of ODM-111, a pain management drug candidate, following a toxicology study suggesting it may not be suitable for long-term use. 25 October 2024
Biotechnology
US artificial intelligence (AI) to gene therapy focussed biotech Dyno Therapeutics today announced its second research collaboration with Roche to develop next-generation adeno-associated virus (AAV) vectors for gene therapies targeting neurological diseases. 24 October 2024
Biotechnology
Shares of Californian clinical-stage biotech Alto Neuroscience plummeted 70% to $4.36 yesterday, as is announced disappointing trial results for depression candidate. 24 October 2024
Pharmaceutical
Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had. 23 October 2024
Biotechnology
After a dearth of advances on the treatment of Alzheimer’s disease for many years, June has become the month of action, with conditional US regulatory approval for the first treatment in 20 years, and two investigational drugs gaining Breakthrough status. 25 June 2021
Pharmaceutical
Japan’s Ministry of Health, Labor and Welfare (MHLW) has granted regulatory approval for Evrysdi (risdiplam) Dry Syrup 60mg for the treatment of spinal muscular atrophy (SMA). 24 June 2021
Biotechnology
The US Food and Drug Administration has granted Breakthrough Therapy designation for lecanemab (BAN2401), an investigational anti-amyloid beta (Aβ) protofibril antibody for the treatment of Alzheimer’s disease (AD), under development by Japanese drug major Eisai and US biotech Biogen . 24 June 2021
Pharmaceutical
As in other industries, the rise of the special purpose acquisition company (SPAC) as a means to going public is becoming more evident in pharma and biotech. 23 June 2021
Biotechnology
AstraZeneca’s Koselugo (selumetinib) has been granted conditional approval in the European Union (EU) for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in pediatric patients with neurofibromatosis type 1 (NF1) aged three years and above. 22 June 2021
Biotechnology
Having scored a historic first last week, with accelerated US regulatory approval for the use of its Aduhelm (aducanumab) as the first treatment in nearly two decades to address an underlying cause of Alzheimer's disease, yesterday US biotech major Biogen (Nasdaq: BIIB) also added to the list of failures in the search for such treatments. 17 June 2021
Pharmaceutical
It has been a busy period for news from Biogen, with a groundbreaking approval in Alzheimer’s followed by the implosion of an expensive rare disease program picked up in 2019. 16 June 2021
Pharmaceutical
Japanese drugmaker Eisai has entered into an agreement to divest its rights for the antiepileptic agent Zonegran (zonisamide) in Europe, the Middle East, Russia, and Australia to UK-based Advanz Pharma. 16 June 2021
Biotechnology
Vyepti (eptinezumab-jjmr) met both co-primary endpoints of the RELIEF study, published today in the Journal of the American Medical Association (JAMA), showing early benefit for time to headache pain freedom, and time to the absence of most bothersome symptoms (MBS), compared to placebo, said Danish CNS specialist Lundbeck. 16 June 2021
Pharmaceutical
Ireland-incorporated Avadel Pharmaceuticals has announced new post hoc analyses of data from the completed pivotal Phase III REST-ON clinical trial of FT218, at SLEEP 2021. 16 June 2021
Biotechnology
Swiss-American biotech CRISPR Therapeutics and USA-based Capsida Biotherapeutics have entered into a strategic partnership to research, develop, manufacture and commercialize in vivo gene editing therapies delivered with engineered AAV vectors for the treatment of familial amyotrophic lateral sclerosis (ALS) and Friedreich’s ataxia. 15 June 2021
Biotechnology
The US Food and Drug Administration last Monday finally approved the use of Biogen’s New Drug Application (NDA) for the use of aducanumab, now trade-named Aduhelm, for the treatment of Alzheimer’s disease. Novartis released positive Phase III data for its iptacopan as a treatment for a rare kidney disease. Last Wednesday, Ocugen revealed that, following a meeting with the FDA, it is seeking approval for its COVID-19 vaccine candidate, Covaxin, through a full Biological License Application (BLA), rather than the faster emergency use authorization process, suggesting that, with the number on vaccines already cleared for EUA, the agency is tightening up the rules. There was negative news from Vertex on Thursday, when the company announced that, although its rare disease candidate VX-864 met its primary endpoint in the latest trial, added to previous results it looks unlikely to provide substantial clinical benefit, so has dropped its development. 13 June 2021
Pharmaceutical
US pharma major AbbVie is to develop and commercialize its portfolio company Caraway Therapeutics’ small molecule therapeutics targeting TMEM175, a potassium ion channel critical to lysosomal function implicated in both Parkinson’s disease (PD) and other neurodegenerative disorders. 10 June 2021
Biotechnology
The launch of Alcyone Therapeutics, a biotech focused on developing gene therapies for central nervous system (CNS) disorders, has been announced. 9 June 2021
Pharmaceutical
Shares of Nippon Chemiphar shot up 22% to 2,771 yen today, after it disclosed a partnership with fellow Japanese drugmaker Sumitomo Dainippon Pharma. 9 June 2021
Biotechnology
The adjectives that accompanied the US approval of the first drug to treat Alzheimer’s disease in nearly two decades sought to sum up the apparent magnitude of the moment. 8 June 2021
Pharmaceutical
London-listed Indivior today announced that it is extending its leadership position in substance use disorder (SUD) treatment by expanding into the under treated cannabis-related disorders, including cannabis use disorder (CUD) and cannabis-induced psychosis (CIP). 8 June 2021
Biotechnology
Marking a landmark decision, the US Food and Drug Administration today approved the first new treatment for Alzheimer’s disease in nearly two decades. 7 June 2021
Biotechnology
Last week’s deal-making news featured US biotech giant Amgen announcing a licensing agreement with Japan’s Kyowa Kirin to develop the latter’s KHK4083 for atopic dermatitis, for a potential $1.2 billion. Also, Australian drug developer Immutep signed a licensing deal with Germany’s Merck KGaA for its PD-1 inhibitor eftilagimod alfa, which also attracted attention at the ASCO meeting. On the regulatory front, Ireland’s Alkermes finally gained US Food and Drug Administration approval for its Lybalvi (olanzapine and samidorphan) for the treatment of schizophrenia and bipolar 1 disorder. Germany’s MorphoSys announced it is acquiring US firm Constellation Pharmaceuticals along with its lead candidates pelabresib and CPI-0209, which are hematological and cancer treatments, respectively, for a total of $1.7 billion. 6 June 2021
Biotechnology
Privately-held US neurology specialist Alzheon today announced the dosing of the first patient in its APOLLOE4 Phase III study evaluating the efficacy and safety of ALZ-801 in early AD patients carrying two copies of the ε4 allele of the apolipoprotein E gene (APOE4/4 homozygotes). 4 June 2021
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze